Financial Data and Key Metrics Changes - Consolidated revenue for fiscal year 2025 reached $1.5 billion, representing a 16% increase year-over-year [5] - Adjusted EBITDA totaled $126 million, with an EBITDA margin of 8%, consistent with the previous year despite revenue growth from lower-margin healthcare services [6][26] - Healthcare Services revenue grew approximately 55% to nearly $500 million, driven by the SelectRx platform [5][11] Business Line Data and Key Metrics Changes - Senior Medicare Advantage business generated $600 million in revenue, with adjusted EBITDA of $162 million, reflecting a 200 basis point increase in EBITDA margins despite a smaller agent workforce [27] - Healthcare Services segment saw membership grow by 31%, with revenue of $743 million and adjusted EBITDA of $25 million, indicating significant progress in scale and profitability [11][30] - Life division revenues grew 10% to $173 million, with a 32% increase in adjusted EBITDA to $27 million, representing a 15% margin [31] Market Data and Key Metrics Changes - The company noted a challenging market backdrop for the Senior Medicare Advantage business due to significant plan changes by carriers and new eligibility parameters [6] - The addressable market for SelectRx is described as massive, with expectations for continued strong growth in healthcare services [30] Company Strategy and Development Direction - The company aims to leverage its information and connectivity advantage within healthcare to drive profitability and cash flow [10][14] - SelectQuote's strategic vision includes becoming a holistic solution provider across the $5 trillion U.S. healthcare market, focusing on efficiency and cash flow generation [13][22] - The company plans to balance growth with sustainable cash flows, with expectations for a flatter year in Medicare Advantage submissions [23][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 20% plus EBITDA margins driven by technology and agent-led models [23] - The company anticipates generating positive operating cash flow in fiscal 2026, with a focus on capital allocation to improve the balance sheet [38] - Management highlighted the importance of technology and AI in enhancing operational efficiency and customer service [17][19] Other Important Information - The company has made significant investments in technology to automate tasks and optimize decision-making, which has improved enrollment times by 25% [20][68] - The Kansas distribution facility is expected to enhance capacity and drive margin improvements in the healthcare services segment [12][44] Q&A Session Summary Question: Can you discuss the path to target margins as SelectRx scales? - Management indicated that as the business scales, they expect to drive variable costs down and enhance margins through automation and operational refinements [40][43] Question: Is there a catalytic level of EBITDA contribution that could accelerate the securitization program? - Management noted that while there is no specific threshold, increasing EBITDA generation will open up various paths for capital structure improvements [46][47] Question: What dynamics have changed regarding SelectRx growth? - Management clarified that while membership growth may slow, they expect strong EBITDA growth due to operational refinements and partnerships with carriers [51][52] Question: How significant is AI in serving more customers? - Management highlighted that AI is used to enhance agent efficiency and improve customer interactions, resulting in significant time savings [54][66] Question: What are the capital allocation priorities moving forward? - Management emphasized the importance of balancing growth with cash flow generation, focusing on improving the capital structure while exploring growth opportunities in healthcare services [74][78]

Financial Performance - FY25 revenue reached $1527 million, exceeding the original guidance of $1450 million[10] - Adjusted EBITDA for FY25 was $126 million, surpassing the original guidance of $105 million[10] - The Senior division achieved a full-year Adjusted EBITDA margin of 27%[10, 35] - Healthcare Services division generated over $25 million in Adjusted EBITDA[10] - FY26 revenue is projected to be between $1650 million and $1750 million, representing an 11% year-over-year increase at the midpoint[30, 50] - FY26 Adjusted EBITDA is projected to be between $120 million and $150 million, a 7% year-over-year increase at the midpoint[50] Senior Division - Agent productivity increased by 24% year-over-year[10] - Senior division's revenue to customer acquisition cost (CAC) multiple improved to 61x[13, 24] - Operating expense per policy in the Senior division decreased to $738[13] - Marketing expense per policy in the Senior division decreased to $394[13] Healthcare Services Division - Healthcare Services revenue grew to $743 million in FY25[17] - Healthcare Services Adjusted EBITDA increased to $25 million in FY25[17] - SelectRx membership reached 108,000[18] Capital Structure - Term debt was reduced from $683 million to $385 million[48]

[Executive Summary & FY2026 Guidance](index=1&type=section&id=Executive%20Summary%20%26%20FY26%20Guidance) [Consolidated Earnings Highlights (Q4 FY2025)](index=1&type=section&id=Consolidated%20Earnings%20Highlights) SelectQuote, Inc. achieved significant financial improvement in Q4 FY2025, with consolidated revenue growth and a swing from net loss to net profit, despite a decrease in Adjusted EBITDA Q4 FY2025 Consolidated Earnings Highlights: | Metric | Q4 FY2025 (million USD) | Q4 FY2024 (million USD) | Change | | :--- | :--- | :--- | :--- | | Consolidated Revenue | 345.1 | 307.2 | +12.3% | | Consolidated Net Income (Loss) | 12.9 | (31.0) | Swung to Profit | | Consolidated Adjusted EBITDA* | 2.7 | 14.4 | -81.3% | [Fiscal Year 2026 Guidance](index=1&type=section&id=Fiscal%20Year%202026%20Guidance) The company issued its financial guidance for FY2026, projecting growth in both revenue and Adjusted EBITDA FY2026 Guidance Range: | Metric | Range (million USD) | | :--- | :--- | | Revenue | 1,650 - 1,750 | | Adjusted EBITDA* | 120 - 150 | [CEO Commentary](index=1&type=section&id=CEO%20Commentary) CEO Tim Danker highlighted the strength of the company's holistic healthcare services model and expressed confidence in future value creation for all stakeholders, noting three consecutive years of exceeding Adjusted EBITDA expectations - The company's holistic healthcare services model performed strongly in FY2025, with expectations for substantial future value creation for all stakeholders[2](index=2&type=chunk) - The company has exceeded initial financial expectations for the third consecutive year, with Adjusted EBITDA surpassing projections by over **20% annually**[2](index=2&type=chunk) [Segment Results Overview](index=2&type=section&id=Segment%20Results%20Overview) [Definition of Segments and Adjusted EBITDA](index=2&type=section&id=Definition%20of%20Segments%20and%20Adjusted%20EBITDA) SelectQuote currently operates three reportable segments: Senior, Healthcare Services, and Life, utilizing Adjusted EBITDA as a key metric for evaluating business operational performance - The company operates three reportable segments: Senior, Healthcare Services, and Life[4](index=4&type=chunk) - Adjusted EBITDA is defined as income (loss) before income tax expense (benefit), plus net interest expense, depreciation and amortization, stock-based compensation, goodwill, long-lived asset and intangible asset impairment, transaction costs, net loss on disposal of property, equipment and software, other non-recurring expenses and income, and fair value changes in warrant liabilities[4](index=4&type=chunk) [Senior Segment](index=2&type=section&id=Senior%20Segment) [Senior Financial Results](index=2&type=section&id=Senior%20Financial%20Results) The Senior segment experienced declines in both revenue and Adjusted EBITDA for Q4 and full-year FY2025, with a notable contraction in Adjusted EBITDA margin during the fourth quarter Senior Segment Financial Results (thousand USD): | Metric | Q4 FY2025 | Q4 FY2024 | QoQ Change | FY2025 | FY2024 | YoY Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Revenue | $82,464 | $114,143 | (28)% | $600,393 | $655,849 | (8)% | | Adjusted EBITDA* | $7,722 | $27,872 | (72)% | $161,671 | $166,744 | (3)% | | Adjusted EBITDA Margin* | 9 % | 24 % | -15pp | 27 % | 25 % | +2pp | [Senior Operating Metrics](index=2&type=section&id=Senior%20Operating%20Metrics) Senior segment operating metrics indicate a decline in submitted and approved policies for Q4 and full-year FY2025, with a slight decrease in the lifetime value of commissions per approved policy, despite growth in other product policies [Submitted Policies](index=2&type=section&id=Submitted%20Policies) Submitted policies decreased in Q4 and full-year FY2025, primarily due to a significant decline in Medicare Advantage plans, though other product submissions saw growth Submitted Policies: | Product | Q4 FY2025 | Q4 FY2024 | QoQ Change | FY2025 | FY2024 | YoY Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Medicare Advantage | 85,979 | 117,091 | (27)% | 674,851 | 720,027 | (6)% | | (1)All Other | 21,438 | 15,260 | 40 % | 87,413 | 72,906 | 20 % | | **Total** | **107,417** | **132,351** | **(19)%** | **762,264** | **792,933** | **(4)%** | [Approved Policies](index=3&type=section&id=Approved%20Policies) Approved policies declined in Q4 and full-year FY2025, mainly driven by a substantial decrease in Medicare Advantage plans, while other product approvals increased Approved Policies: | Product | Q4 FY2025 | Q4 FY2024 | QoQ Change | FY2025 | FY2024 | YoY Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Medicare Advantage | 85,344 | 107,272 | (20)% | 592,874 | 625,245 | (5)% | | (1)All Other | 19,979 | 13,849 | 44 % | 70,295 | 62,419 | 13 % | | **Total** | **105,323** | **121,121** | **(13)%** | **663,169** | **687,664** | **(4)%** | [Lifetime Value of Commissions per Approved Policy](index=3&type=section&id=Lifetime%20Value%20of%20Commissions%20per%20Approved%20Policy) The lifetime value of commissions per approved policy slightly decreased in Q4 and full-year FY2025, with a more significant decline observed in other products Lifetime Value of Commissions per Approved Policy (USD per Policy): | Product | Q4 FY2025 | Q4 FY2024 | QoQ Change | FY2025 | FY2024 | YoY Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Medicare Advantage | $837 | $847 | (1)% | $884 | $910 | (3)% | | (1)All Other | $125 | $186 | (33)% | $134 | $146 | (8)% | [Healthcare Services Segment](index=3&type=section&id=Healthcare%20Services%20Segment) [Healthcare Services Financial Results](index=3&type=section&id=Healthcare%20Services%20Financial%20Results) The Healthcare Services segment achieved significant revenue and Adjusted EBITDA growth in Q4 and full-year FY2025, accompanied by substantial margin expansion Healthcare Services Segment Financial Results (thousand USD): | Metric | Q4 FY2025 | Q4 FY2024 | QoQ Change | FY2025 | FY2024 | YoY Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Revenue | $214,028 | $145,223 | 47 % | $742,705 | $478,508 | 55 % | | Adjusted EBITDA* | $11,853 | $909 | 1,204 % | $25,387 | $7,821 | 225 % | | Adjusted EBITDA Margin* | 6 % | 1 % | +5pp | 3 % | 2 % | +1pp | [Healthcare Services Operating Metrics](index=3&type=section&id=Healthcare%20Services%20Operating%20Metrics) Healthcare Services segment operating metrics show substantial growth in both SelectRx members and daily prescription shipments, reflecting successful membership growth strategies [SelectRx Members](index=5&type=section&id=SelectRx%20Members) As of June 30, 2025, total SelectRx members increased by 31% year-over-year, driven by the company's proactive membership growth strategy Total SelectRx Members: | Date | Members | | :--- | :--- | | June 30, 2025 | 108,018 | | June 30, 2024 | 82,385 | - SelectRx member count increased by **31% year-over-year**, primarily due to the company's strategy to grow SelectRx membership[16](index=16&type=chunk) [Prescriptions Per Day](index=5&type=section&id=Prescriptions%20Per%20Day) Daily prescription shipments demonstrated significant growth in both Q4 and full-year FY2025 Daily Prescription Shipments: | Period | Q4 FY2025 | Q4 FY2024 | FY2025 | FY2024 | | :--- | :--- | :--- | :--- | :--- | | Daily Prescriptions | 30,630 | 22,950 | 27,867 | 18,935 | [Combined Senior and Healthcare Services - Consumer Per Unit Economics](index=5&type=section&id=Combined%20Senior%20and%20Healthcare%20Services%20-%20Consumer%20Per%20Unit%20Economics) [Per Unit Economics Analysis](index=5&type=section&id=Per%20Unit%20Economics%20Analysis) For the twelve months ended June 30, 2025, combined Senior and Healthcare Services total revenue per MA/MS approved policy grew by 22%, primarily due to increased pharmacy revenue, while total operating expenses also rose with business expansion Combined Senior and Healthcare Services Consumer Per Unit Economics (USD per Approved Policy): | Metric | As of June 30, 2025 (12 months) | As of June 30, 2024 (12 months) | | :--- | :--- | :--- | | MA and MS Approved Policies | 594,572 | 627,130 | | MA and MS Commissions per MA/MS Policy | $885 | $910 | | Other Commissions per MA/MS Policy | $12 | $12 | | Pharmacy Revenue per MA/MS Policy | $1,219 | $741 | | Other Revenue per MA/MS Policy | $86 | $146 | | **Total Revenue per MA/MS Policy** | **$2,202** | **$1,809** | | Total Operating Expenses per MA/MS Policy | ($1,937) | ($1,530) | | Adjusted EBITDA* per MA/MS Policy | $265 | $279 | | Adjusted EBITDA Margin* per MA/MS Policy | 12 % | 15 % | | Revenue/Customer Acquisition Cost Multiple | 6.1X | 4.5X | - Total revenue per MA/MS approved policy increased by **22%** for the twelve months ended June 30, 2025, primarily due to increased pharmacy revenue[21](index=21&type=chunk) - Total operating expenses per MA/MS approved policy increased by **27%** for the twelve months ended June 30, 2025, driven by higher cost of goods sold for the Healthcare Services business growth[21](index=21&type=chunk) [Life Segment](index=6&type=section&id=Life%20Segment) [Life Financial Results](index=6&type=section&id=Life%20Financial%20Results) The Life segment reported revenue growth in Q4 and full-year FY2025, with full-year Adjusted EBITDA significantly increasing, though Q4 Adjusted EBITDA saw a slight decline Life Segment Financial Results (thousand USD): | Metric | Q4 FY2025 | Q4 FY2024 | QoQ Change | FY2025 | FY2024 | YoY Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Revenue | $47,984 | $42,074 | 14 % | $172,978 | $157,930 | 10 % | | Adjusted EBITDA* | $6,922 | $7,217 | (4)% | $26,669 | $20,164 | 32 % | | Adjusted EBITDA Margin* | 14 % | 17 % | -3pp | 15 % | 13 % | +2pp | [Life Operating Metrics](index=6&type=section&id=Life%20Operating%20Metrics) Life segment operating metrics show overall premium growth in Q4 and full-year FY2025, with permanent life insurance premiums experiencing particularly strong increases Term and Permanent Life Insurance Premiums (thousand USD): | Premium Type | Q4 FY2025 | Q4 FY2024 | QoQ Change | FY2025 | FY2024 | YoY Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Term Life Premiums | $19,989 | $18,074 | 11 % | $71,448 | $70,450 | 1 % | | Permanent Life Premiums | $30,807 | $23,789 | 30 % | $105,099 | $86,600 | 21 % | | **Total** | **$50,796** | **$41,863** | **21 %** | **$176,547** | **$157,050** | **12 %** | [Non-GAAP Financial Measures](index=7&type=section&id=Non-GAAP%20Financial%20Measures) [Definition and Reconciliation Note](index=7&type=section&id=Definition%20and%20Reconciliation%20Note) This report includes non-GAAP financial measures, such as Adjusted EBITDA, intended to supplement rather than replace GAAP metrics; management and the board use Adjusted EBITDA to assess operational performance, but forward-looking quantitative reconciliation to the most directly comparable GAAP measure is not provided due to the unpredictability of certain information - Adjusted EBITDA is a non-GAAP financial measure defined as net income (loss) before income tax expense (benefit), plus interest expense, depreciation and amortization, fair value changes in warrant liabilities, and certain non-cash or non-recurring expenses (including restructuring and stock-based compensation expenses)[26](index=26&type=chunk) - Company management and the board of directors use Adjusted EBITDA to understand and evaluate operational performance, and to set budgets and operational goals[26](index=26&type=chunk) - The company cannot provide a quantitative reconciliation of forward-looking Adjusted EBITDA to the most directly comparable GAAP measure because certain information, such as warrant fair value, cannot be reasonably predicted[27](index=27&type=chunk) [Forward-Looking Statements & Risk Factors](index=7&type=section&id=Forward-Looking%20Statements%20%26%20Risk%20Factors) [Forward-Looking Statements](index=7&type=section&id=Forward-Looking%20Statements) This report contains forward-looking statements reflecting the company's current views on future events and financial performance, which are not historical facts and are subject to unpredictable risks, assumptions, and uncertainties - Forward-looking statements reflect the company's current views on future events and financial performance, but are not historical facts and are based on current expectations, estimates, and projections[28](index=28&type=chunk) - These statements are subject to unpredictable risks, assumptions, and uncertainties, and actual results may differ materially from those expressed or implied by forward-looking statements[28](index=28&type=chunk) [Risk Factors](index=7&type=section&id=Risk%20Factors) Key factors that could cause actual results to differ materially from forward-looking statements include reliance on a few insurance carrier partners, changes in health insurance market regulations, competition, dependence on Senior segment revenue, ability to attract and retain qualified personnel, reliance on lead providers, data access and accuracy, global economic conditions, and technology infrastructure disruptions - Key risk factors include: reliance on a few insurance carrier partners, impact of existing and future laws and regulations in the health insurance market, changes in health insurance products and markets, competition from direct sales, dependence on Senior segment revenue, ability to attract and retain qualified personnel, reliance on lead providers, data access and accuracy, cost-effective advertising, global economic conditions, acquisition disruptions, significant estimates and assumptions in financial statements, goodwill impairment, existing or potential litigation, existing and future indebtedness, ability to comply with debt covenants, access to additional capital, intellectual property protection, seasonality, accuracy and timeliness of commission reporting, timing of insurance carrier approvals and payments, factors affecting lifetime value of commissions estimates, changes in accounting rules and tax laws, technology infrastructure disruptions, relationships with third-party service providers, cybersecurity breaches, and pharmacy business-related factors[29](index=29&type=chunk)[30](index=30&type=chunk) [About SelectQuote](index=8&type=section&id=About%20SelectQuote) [Company Overview and Business Lines](index=8&type=section&id=Company%20Overview%20and%20Business%20Lines) Founded in 1985, SelectQuote provides insurance solutions to consumers by offering unbiased comparisons from multiple highly-rated carriers, leveraging skilled agents and proprietary technology across its three core business lines: SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life - SelectQuote was founded in 1985, helping consumers choose the most appropriate policies by providing unbiased comparisons from multiple highly-rated insurance carriers[31](index=31&type=chunk) - The company's success is built on two pillars: highly-trained agents offering consultative needs analysis and proprietary technology for acquiring and distributing high-quality leads[31](index=31&type=chunk) - The company currently operates three core business lines: SelectQuote Senior (senior insurance), SelectQuote Healthcare Services (healthcare services, including SelectRx pharmacy and chronic care management services), and SelectQuote Life (life insurance)[32](index=32&type=chunk) [Financial Statements](index=9&type=section&id=Financial%20Statements) [Consolidated Balance Sheets](index=9&type=section&id=Consolidated%20Balance%20Sheets) As of June 30, 2025, SelectQuote's consolidated total assets slightly increased, while total liabilities significantly decreased, and total stockholders' equity rose, primarily due to the issuance of preferred stock Consolidated Balance Sheets (thousand USD): | Metric | June 30, 2025 | June 30, 2024 | | :--- | :--- | :--- | | Total Assets | $1,249,356 | $1,193,908 | | Total Liabilities | $673,838 | $877,107 | | Preferred Stock | $224,374 | — | | Total Stockholders' Equity | $351,144 | $316,801 | [Consolidated Statements of Comprehensive Income (Loss)](index=11&type=section&id=Consolidated%20Statements%20of%20Comprehensive%20Income%20(Loss)) SelectQuote achieved revenue growth and a swing from net loss to net profit in Q4 and full-year FY2025, though net income attributable to common stockholders remained a loss in the fourth quarter Consolidated Statements of Comprehensive Income (Loss) (thousand USD): | Metric | Q4 FY2025 | Q4 FY2024 | FY2025 | FY2024 | | :--- | :--- | :--- | :--- | :--- | | Total Revenue | $345,102 | $307,208 | $1,526,594 | $1,321,776 | | Operating Income (Loss) | ($12,522) | ($1,391) | $68,499 | $64,550 | | Net Income (Loss) | $12,868 | ($31,017) | $47,580 | ($34,125) | | Net Income (Loss) Attributable to Common Stockholders | ($3,894) | ($31,017) | $25,032 | ($34,125) | | Basic Earnings (Loss) Per Share | ($0.02) | ($0.18) | $0.14 | ($0.20) | | Diluted Earnings (Loss) Per Share | ($0.02) | ($0.18) | $0.01 | ($0.20) | [Consolidated Statements of Cash Flows](index=12&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) In FY2025, the company experienced cash outflows from operating and investing activities, offset by cash inflows from financing activities, resulting in a net decrease in cash, cash equivalents, and restricted cash Consolidated Statements of Cash Flows (thousand USD): | Cash Flow Type | Q4 FY2025 | Q4 FY2024 | FY2025 | FY2024 | | :--- | :--- | :--- | :--- | :--- | | Net Cash from Operating Activities | ($37,482) | $19,995 | ($11,666) | $15,236 | | Net Cash from Investing Activities | ($3,111) | ($5,920) | ($11,314) | ($14,846) | | Net Cash from Financing Activities | ($8,563) | ($9,193) | $17,356 | ($40,856) | | Net Increase (Decrease) in Cash, Cash Equivalents, and Restricted Cash | ($49,156) | $4,882 | ($5,624) | ($40,466) | | End of Period Cash, Cash Equivalents, and Restricted Cash | $37,066 | $42,690 | $37,066 | $42,690 | [Adjusted EBITDA Reconciliation](index=13&type=section&id=Adjusted%20EBITDA%20Reconciliation) [Q4 FY2025 Reconciliation](index=13&type=section&id=Q4%20FY25%20Reconciliation) In Q4 FY2025, the company's total Adjusted EBITDA was $26,497 thousand, leading to income before income tax expense (benefit) of $9,375 thousand after various adjustments Q4 FY2025 Adjusted EBITDA to Income Before Income Tax Expense (Benefit) Reconciliation (thousand USD): | Item | Amount | | :--- | :--- | | Senior Segment Adjusted EBITDA | $7,722 | | Healthcare Services Segment Adjusted EBITDA | $11,853 | | Life Segment Adjusted EBITDA | $6,922 | | **Total Adjusted Segment EBITDA** | **$26,497** | | All Other Adjusted EBITDA | $950 | | Corporate | ($24,753) | | Stock-based Compensation Expense | ($4,852) | | Transaction Costs | ($1,257) | | Depreciation and Amortization | ($4,876) | | Net Loss on Disposal of Property, Equipment and Software | ($80) | | Long-lived Asset Impairment | ($4,209) | | Fair Value Change in Warrant Liabilities | $34,181 | | Net Interest Expense | ($12,226) | | **Income Before Income Tax Expense (Benefit)** | **$9,375** | [Q4 FY2024 Reconciliation](index=13&type=section&id=Q4%20FY24%20Reconciliation) In Q4 FY2024, the company's total Adjusted EBITDA was $35,998 thousand, resulting in a loss before income tax expense (benefit) of $24,815 thousand after various adjustments Q4 FY2024 Adjusted EBITDA to Loss Before Income Tax Expense (Benefit) Reconciliation (thousand USD): | Item | Amount | | :--- | :--- | | Senior Segment Adjusted EBITDA | $27,872 | | Healthcare Services Segment Adjusted EBITDA | $909 | | Life Segment Adjusted EBITDA | $7,217 | | **Total Adjusted Segment EBITDA** | **$35,998** | | All Other Adjusted EBITDA | $2,474 | | Corporate | ($24,115) | | Stock-based Compensation Expense | ($3,304) | | Transaction Costs | ($5,529) | | Depreciation and Amortization | ($6,407) | | Net Loss on Disposal of Property, Equipment and Software | ($523) | | Net Interest Expense | ($23,409) | | **Loss Before Income Tax Expense (Benefit)** | **($24,815)** | [FY2025 Reconciliation](index=14&type=section&id=FY25%20Reconciliation) For full-year FY2025, the company's total Adjusted EBITDA was $213,727 thousand, leading to income before income tax expense (benefit) of $48,511 thousand after various adjustments FY2025 Adjusted EBITDA to Income Before Income Tax Expense (Benefit) Reconciliation (thousand USD): | Item | Amount | | :--- | :--- | | Senior Segment Adjusted EBITDA | $161,671 | | Healthcare Services Segment Adjusted EBITDA | $25,387 | | Life Segment Adjusted EBITDA | $26,669 | | **Total Adjusted Segment EBITDA** | **$213,727** | | All Other Adjusted EBITDA | $10,597 | | Corporate | ($98,070) | | Stock-based Compensation Expense | ($18,357) | | Transaction Costs | ($14,617) | | Depreciation and Amortization | ($20,460) | | Net Loss on Disposal of Property, Equipment and Software | ($240) | | Long-lived Asset Impairment | ($4,209) | | Fair Value Change in Warrant Liabilities | $59,525 | | Net Interest Expense | ($79,385) | | **Income Before Income Tax Expense (Benefit)** | **$48,511** | [FY2024 Reconciliation](index=16&type=section&id=FY24%20Reconciliation) For full-year FY2024, the company's total Adjusted EBITDA was $194,729 thousand, resulting in a loss before income tax expense (benefit) of $29,066 thousand after various adjustments FY2024 Adjusted EBITDA to Loss Before Income Tax Expense (Benefit) Reconciliation (thousand USD): | Item | Amount | | :--- | :--- | | Senior Segment Adjusted EBITDA | $166,744 | | Healthcare Services Segment Adjusted EBITDA | $7,821 | | Life Segment Adjusted EBITDA | $20,164 | | **Total Adjusted Segment EBITDA** | **$194,729** | | All Other Adjusted EBITDA | $14,127 | | Corporate | ($91,863) | | Stock-based Compensation Expense | ($13,816) | | Transaction Costs | ($13,158) | | Depreciation and Amortization | ($24,998) | | Net Loss on Disposal of Property, Equipment and Software | ($536) | | Net Interest Expense | ($93,551) | | **Loss Before Income Tax Expense (Benefit)** | **($29,066)** | [Additional Information](index=7&type=section&id=Additional%20Information) [Earnings Conference Call](index=7&type=section&id=Earnings%20Conference%20Call) SelectQuote, Inc. will host an earnings conference call on August 21, 2025, at 8:30 AM ET, with investor participation available via a registration link or the investor relations website - The earnings conference call will be held on August 21, 2025, at 8:30 AM ET[25](index=25&type=chunk) - Investors can participate via the registration link https://registrations.events/direct/Q4I547808 or the company's investor relations website https://ir.selectquote.com/investor-home/default.aspx[25](index=25&type=chunk) [Investor Relations & Media Contact](index=8&type=section&id=Investor%20Relations%20%26%20Media%20Contact) Detailed contact information for investor relations and media is provided - Investor Relations Contact: Sloan Bohlen, Phone: 877-678-4083, Email: investorrelations@selectquote.com[33](index=33&type=chunk) - Media Contact: Matt Gunter, Phone: 913-286-4931, Email: matt.gunter@selectquote.com[33](index=33&type=chunk)

Core Viewpoint - A securities class action lawsuit has been filed against SelectQuote, Inc. for allegedly misleading investors regarding its business practices and compliance with regulations [1][2]. Allegations - The lawsuit claims that SelectQuote and its executives failed to disclose that they steered Medicare beneficiaries to insurance plans that paid the highest commissions rather than those best suited for customers [8] - It is alleged that SelectQuote did not provide unbiased Medicare Advantage comparisons as claimed [8] - The company is accused of accepting illegal kickbacks to favor certain insurers, which limited competition [8] - SelectQuote is said to have been non-compliant with laws, regulations, and contracts, exposing it to regulatory and legal risks, including under the False Claims Act [8] - Positive statements made by the company regarding its business and prospects were misleading and lacked a reasonable basis [8] Impact on Investors - Following the announcement by the U.S. Department of Justice on May 1, 2025, SelectQuote's stock price fell by 19.2%, decreasing by $0.61 to close at $2.56 per share [3].

Core Viewpoint - Investors in SelectQuote, Inc. have the opportunity to lead a securities fraud class action lawsuit due to alleged misconduct by the company [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit alleges that from September 9, 2020, to May 1, 2025, SelectQuote failed to disclose critical information to investors, including: - The company directed Medicare beneficiaries to insurers that compensated SelectQuote the most, regardless of plan quality [2]. - SelectQuote did not provide unbiased comparisons for Medicare Advantage insurance plans [2]. - The company received illegal kickbacks to steer beneficiaries to certain insurers while limiting enrollment in competitors' plans [2]. - SelectQuote's actions resulted in non-compliance with laws, regulations, and contractual obligations [2]. - The company was at risk of regulatory and legal sanctions, including potential violations of the False Claims Act [2]. - Positive statements made by the defendants regarding the company's business and prospects were materially misleading [2]. Participation Information - Investors who suffered losses in SelectQuote are encouraged to participate in the ongoing lawsuit before the lead plaintiff deadline of October 10, 2025 [2]. - Interested parties can contact the Law Offices of Frank R. Cruz for more information [3][4].

Core Viewpoint - A securities class action lawsuit has been filed against SelectQuote, Inc. for allegedly misleading investors regarding its business practices and compliance with regulations [1][2]. Allegations - SelectQuote allegedly steered Medicare beneficiaries to insurance plans that provided the highest commissions rather than those best suited for customers [7]. - The company is accused of failing to provide unbiased Medicare Advantage comparisons as claimed [7]. - SelectQuote reportedly accepted illegal kickbacks to favor certain insurers, limiting competition [7]. - The company is alleged to have been non-compliant with laws, regulations, and contracts, exposing it to regulatory and legal risks, including under the False Claims Act [7]. - Positive statements made by SelectQuote about its business and prospects were misleading and lacked a reasonable basis [7]. Impact on Investors - Following the announcement by the U.S. Department of Justice on May 1, 2025, SelectQuote's stock price fell by 19.2%, decreasing by $0.61 to close at $2.56 per share [3]. Legal Context - Investors have until October 10, 2025, to seek appointment as lead plaintiff in the case [4]. - The law firm representing the investors, Wolf Haldenstein Adler Freeman & Herz LLP, has over 125 years of experience in securities litigation [4]. Key Events - The U.S. Department of Justice filed a False Claims Act complaint against SelectQuote, alleging that from 2016 to 2021, the company received tens of millions of dollars in illegal kickbacks from insurers [7]. - The DOJ also alleged that SelectQuote conspired with major insurers to discriminate against less profitable beneficiaries, including those with disabilities [7]. - The DOJ concluded that SelectQuote falsely claimed to provide "unbiased coverage comparisons" while steering customers toward higher-paying plans [7].

Core Viewpoint - A securities class action lawsuit has been filed against SelectQuote following the U.S. Department of Justice's intervention in a separate lawsuit, leading to a significant 19% drop in the company's stock price on May 1, 2025 [1][4]. Group 1: Lawsuit Details - The class action, Pahlkotter v. SelectQuote, Inc. et al., seeks to represent investors who acquired SelectQuote securities between September 9, 2020, and May 1, 2025 [2]. - The lead plaintiff deadline for the lawsuit is set for October 10, 2025 [2]. Group 2: Allegations Against SelectQuote - The lawsuit alleges that SelectQuote made false and misleading statements regarding its business practices, particularly in its Medicare Advantage sales [3]. - The DOJ claims that from 2016 to at least 2021, SelectQuote received "tens of millions of dollars" in illegal kickbacks for directing Medicare beneficiaries to specific plans, contradicting its claims of providing unbiased advice [3][8]. - The company allegedly discriminated against less profitable beneficiaries and directed customers to the highest-paying plans, which raises concerns about compliance with applicable laws [3][8]. Group 3: Impact on Stock and Investor Sentiment - Following the announcement of the DOJ's involvement and the class action lawsuit, SelectQuote's stock price has continued to decline, indicating a significant impact on the company's market value [4]. - Hagens Berman is investigating the extent to which SelectQuote's alleged practices may have inflated its financial results, leading to investor losses [7][9].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against SelectQuote, Inc. due to allegations of misleading practices related to Medicare insurance plans, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by October 10, 2025 [4]. Group 1: Allegations Against SelectQuote - The complaint alleges that SelectQuote and its executives violated federal securities laws by making false and misleading statements, including directing Medicare beneficiaries to plans that compensated SelectQuote the most, regardless of quality [6]. - It is claimed that SelectQuote did not provide unbiased comparisons for Medicare Advantage plans and received illegal kickbacks to steer beneficiaries towards certain insurers [6]. - The U.S. Department of Justice filed a complaint stating that from 2016 to at least 2021, SelectQuote received tens of millions of dollars in illegal kickbacks, leading to materially false claims about offering unbiased coverage comparisons [7]. Group 2: Financial Impact - Following the DOJ's allegations, SelectQuote's stock price fell by $0.61, or 19.2%, closing at $2.56 per share on May 1, 2025, amid unusually heavy trading volume [7]. Group 3: Legal Proceedings - Investors who suffered losses exceeding $75,000 in SelectQuote between September 9, 2020, and May 1, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights [1]. - The role of lead plaintiff in the class action is open to any member of the putative class, with the ability to share in any recovery not affected by the decision to serve as lead plaintiff [8].

Core Viewpoint - The article discusses a class action lawsuit against SelectQuote, Inc. due to allegations of receiving illegal kickbacks from health insurance companies and misleading investors about its business practices [1][2][3]. Group 1: Allegations and Legal Actions - The U.S. Department of Justice filed a False Claims Act complaint against SelectQuote, alleging that from 2016 to at least 2021, the company received "tens of millions of dollars" in illegal kickbacks for steering Medicare beneficiaries to specific insurers [2]. - SelectQuote is accused of making materially false claims regarding its services, claiming to offer unbiased coverage comparisons while directing beneficiaries to plans that paid the most [2][3]. - The class action lawsuit alleges that SelectQuote failed to disclose critical information about its operations, including the receipt of illegal kickbacks and non-compliance with applicable laws [3]. Group 2: Financial Impact - Following the DOJ's announcement, SelectQuote's stock price dropped by $0.61, or 19.2%, closing at $2.56 per share on May 1, 2025, with unusually high trading volume [2]. Group 3: Class Action Participation - Investors who purchased SelectQuote securities during the specified Class Period (September 9, 2020, to May 1, 2025) have until October 10, 2025, to file a lead plaintiff motion in the class action lawsuit [1][4].

Should You Join This Class Action Lawsuit? NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of SelectQuote, Inc. ("SelectQuote" or the "Company") (NYSE: SLQT) between September 9, 2020 and May 1, 2025, inclusive. If you purchased or acquired SelectQuote securities, and/or would like to discuss your legal rights and options please visit Selec ...